Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Adenocarcinoma 1

Interventions

Cyclophosphamide 2043Radiotherapy 1859Cisplatin 1826Carboplatin 1533Gemcitabine 1435Paclitaxel 1291Bevacizumab 1271Docetaxel 1202pembrolizumab 1201Oxaliplatin 1160Capecitabine 1145Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 864Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 609fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Interventional × LY3022855 × Clear all
NCT03153410 2025-01-09

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
11 enrolled 14 charts
Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT03101254 2024-07-17

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
5 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡